"We remain committed to accelerating revenue growth, expanding our margins and enhancing productivity..." - Chris Simon
— Chris Simon
03Detailed Report
HAE
Haemonetics Corporation
Period
Q1 2025
CurrencyUSD
Report TypeQuarterly Earnings
GeneratedJun 28, 2026
Swipe to view all report sections
Executive Summary
Haemonetics Corporation (HAE) reported its Q1 2025 financial results showcasing a revenue of $336.2 million, with an 8% increase on a reported basis but a decrease in organic growth of 3%. Management highlighted strategic advancements in technology and product integration, particularly in the Plasma and Hospital segments, as critical to navigating current market dynamics impacted by external challenges. The company maintained guidance for growth amidst reinvestment in innovation and market expansion, particularly in response to heightened demand for blood components and plasma therapies. However, challenges persisted in specific customer transitions and supply chain adaptations.
Key Performance Indicators
Revenue
Increasing
336.17M
QoQ: -2.07% | YoY: 7.98%
Gross Profit
Increasing
174.92M
52.03% margin
QoQ: 1.94% | YoY: 4.58%
Operating Income
Decreasing
39.76M
QoQ: -22.30% | YoY: -25.91%
Net Income
Decreasing
38.37M
QoQ: 88.41% | YoY: -6.50%
EPS
Decreasing
0.75
QoQ: 87.50% | YoY: -7.41%
Revenue Trend
Margin Analysis
Financial Highlights
### Financial Performance Metrics:
- Revenue: $336.2 million (YoY growth: 8%, QoQ decline: 2.07%)
- Net Income: $38.4 million (YoY decline: 6.50%, QoQ increase: 88.41%)
- EBITDA: $68.892 million
- Gross Profit Margin: 52.03%
- Operating Income: $39.756 million, down 25.91% YoY, operating margin: 11.8%
- Earnings Per Share (EPS): Adjusted EPS of $1.02, down 3% YoY
The decrease in organic growth was attributed to transitional dynamics affecting core Plasma revenue, while Hospital business forecasted revenue growth of 27-32%.
Income Statement
Metric
Value
YoY Change
QoQ Change
Revenue
336.17M
7.98%
-2.07%
Gross Profit
174.92M
4.58%
1.94%
Operating Income
39.76M
-25.91%
-22.30%
Net Income
38.37M
-6.50%
88.41%
EPS
0.75
-7.41%
87.50%
Key Financial Ratios
Gross Profit Margin
Good
52.00%
Gross profit margin is healthy and competitive within industry standards
Operating Profit Margin
Fair
11.80%
Operating margin is moderate, room for improvement in cost management
Net Profit Margin
Good
11.40%
Net profit margin is healthy and competitive within industry standards
Return on Assets
Weak
1.51%
Return on assets suggests inefficient capital allocation
Return on Equity
Weak
4.24%
Return on equity suggests inefficient capital allocation
Current Ratio
Strong
3.76
Current ratio indicates excellent liquidity and financial flexibility
Debt to Equity
High Risk
1.35
Debt-to-equity indicates high leverage and elevated financial risk
P/E Ratio
Growth
27.46x
Elevated P/E suggests growth expectations or premium valuation
Price to Book
Premium
4.66x
Trading at premium to book value, reflects strong intangibles or growth
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.